YourVoice.Now Summary
Your MoneyCorporate BenefitsTransparency & AccountabilityMore cancer drugs would be tested in kids — and drug makers could keep earning fast-review passes through 2030.
Your Money
Today the FDA can make a company test a new cancer drug by itself in kids. This bill would also let it require a test of that drug paired with another cancer drug. The change would reach only drugs filed three years or more after it becomes law.
Those studies would have to use forms of the drug suited to each age group tested. They would have to report on dose, safety, and early signs that the drug works, so the label can guide doctors treating children.
Corporate Benefits
A company that wins approval for a rare childhood disease drug earns a voucher for a faster FDA review of any drug it picks. Vouchers can be sold to other companies, and recent ones went for over $100 million. This bill would let the FDA keep awarding them through September 30, 2030.
The FDA could ask for a paired study only in two cases. One is when the drug has a single new active ingredient. The other is when it mixes ingredients already cleared on their own for adult cancer, but never cleared as a pair. Other drugs would fall outside the rule.
Companies with certain new cancer drugs could be told to run an extra study in kids. It would test the drug paired with another. That means more cost and time before approval.
When a company files its first pediatric study plan, the FDA could ask for results from lab studies it has already finished. The agency may do this, but does not have to.
Transparency & Accountability
The Government Accountability Office is the watchdog that audits federal programs. It would study the voucher program and report to Congress within five years. It would look at which firms earned and used vouchers, how big they were, and what the vouchers sold for. It would also ask whether the reward brought new treatments.
The voucher program does not run forever, so Congress has to renew it. This bill would set the cutoff at September 30, 2030. A law passed in February 2026 already runs the program through September 30, 2029.
Within a year, the FDA would have to put out draft guidance on how it will apply the new study rules. The public gets a window to comment. The agency would then have a year after that window closes to finalize the guidance.
More about this bill
Most households would notice nothing here. If your child is treated for cancer, though, this is about the drugs they may be offered years from now. The FDA can already make a drug company test a new cancer drug in children. Under this measure, the agency could also require testing of that drug paired with a drug already used against cancer. Those studies would have to use forms suited to each age group. They would have to report on dose, safety, and early signs that the drug helps. The rules would only reach applications filed three years or more after it becomes law. The measure would also keep a reward program for rare childhood diseases running through September 30, 2030. A company that wins such an approval earns a voucher. The voucher buys a faster FDA review of any drug the company picks. Vouchers can be sold, and recent ones went for over $100 million. Today that program already runs through September 30, 2029, under a law passed in February 2026. Congress's watchdog would report within five years on who earned vouchers, what they sold for, and whether the reward worked.
Congressional Summary
This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2030. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Details
- Congress
- 119th
- Chamber
- Status
- summarized
- Action
- Action Date
- Date Added
- 2026-04-02
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.